IRIS UniCatt

Pugliese, Daniela
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 5.175
AS - Asia 2.918
EU - Europa 2.556
SA - Sud America 723
Continente sconosciuto - Info sul continente non disponibili 171
AF - Africa 97
AN - Antartide 1
OC - Oceania 1
Totale 11.642
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 4.961
SG - Singapore 1.333
DE - Germania 618
CN - Cina 609
BR - Brasile 568
IT - Italia 452
SE - Svezia 395
VN - Vietnam 300
FR - Francia 297
GB - Regno Unito 187
IN - India 126
IE - Irlanda 117
CA - Canada 105
FI - Finlandia 103
UA - Ucraina 97
ID - Indonesia 95
BD - Bangladesh 87
JP - Giappone 79
AR - Argentina 61
RU - Federazione Russa 61
HK - Hong Kong 50
PL - Polonia 50
KR - Corea 41
TR - Turchia 41
NL - Olanda 38
MX - Messico 36
ES - Italia 35
EC - Ecuador 28
IQ - Iraq 28
AT - Austria 26
CO - Colombia 26
ZA - Sudafrica 25
JM - Giamaica 18
BE - Belgio 15
IL - Israele 15
SA - Arabia Saudita 15
VE - Venezuela 14
CZ - Repubblica Ceca 13
MA - Marocco 13
PH - Filippine 13
CI - Costa d'Avorio 12
UZ - Uzbekistan 12
IR - Iran 11
PK - Pakistan 11
CR - Costa Rica 9
EG - Egitto 9
JO - Giordania 9
TT - Trinidad e Tobago 9
CH - Svizzera 8
KE - Kenya 8
UY - Uruguay 8
DZ - Algeria 7
LT - Lituania 7
PR - Porto Rico 7
TN - Tunisia 7
AE - Emirati Arabi Uniti 6
NI - Nicaragua 6
PE - Perù 6
SV - El Salvador 6
CL - Cile 5
HN - Honduras 5
HU - Ungheria 5
NP - Nepal 5
AL - Albania 4
AZ - Azerbaigian 4
BG - Bulgaria 4
CW - ???statistics.table.value.countryCode.CW??? 4
RO - Romania 4
SC - Seychelles 4
BB - Barbados 3
EE - Estonia 3
ET - Etiopia 3
GP - Guadalupe 3
KZ - Kazakistan 3
LV - Lettonia 3
OM - Oman 3
PT - Portogallo 3
PY - Paraguay 3
A2 - ???statistics.table.value.countryCode.A2??? 2
AO - Angola 2
BH - Bahrain 2
BN - Brunei Darussalam 2
BO - Bolivia 2
DK - Danimarca 2
GA - Gabon 2
GT - Guatemala 2
HR - Croazia 2
KG - Kirghizistan 2
KW - Kuwait 2
LB - Libano 2
MM - Myanmar 2
MY - Malesia 2
RS - Serbia 2
AM - Armenia 1
AQ - Antartide 1
AU - Australia 1
AW - Aruba 1
BA - Bosnia-Erzegovina 1
CG - Congo 1
CU - Cuba 1
Totale 11.457
Salva come PNG Salva come JPEG
Città #
Singapore 758
Ashburn 582
San Jose 548
Chandler 452
New York 182
Beijing 173
Los Angeles 142
Dublin 112
Council Bluffs 102
Ho Chi Minh City 97
Jacksonville 89
Hefei 86
The Dalles 82
Lauterbourg 81
Jakarta 75
Tokyo 71
Rome 70
Hanoi 65
Munich 65
Milan 64
Dallas 62
Frankfurt am Main 62
San Mateo 61
Dearborn 54
São Paulo 49
Boston 46
Ann Arbor 44
Hong Kong 44
North Bergen 44
Cattolica 43
Chicago 43
Santa Clara 42
Helsinki 40
Seoul 39
Houston 38
Warsaw 35
Princeton 34
Wilmington 34
Brooklyn 33
Boardman 32
Moscow 31
Nürnberg 30
Nanjing 29
Atlanta 28
Marseille 28
Paris 28
Phoenix 28
Hyderabad 27
Montreal 27
Buffalo 26
Denver 25
Toronto 25
Bremen 23
Kent 23
Turku 23
London 22
Orem 22
Seattle 22
Stockholm 22
Nuremberg 21
Lappeenranta 20
St Louis 20
Da Nang 19
Chennai 18
Düsseldorf 18
Lancaster 17
Lawrence 17
Detroit 16
Johannesburg 16
Memphis 16
San Francisco 16
Belo Horizonte 15
Brussels 15
Fairfield 15
Philadelphia 15
Washington 15
Amsterdam 14
Baghdad 14
Haiphong 14
Redwood City 14
Rio de Janeiro 13
Abidjan 12
Brasília 12
Cagliari 12
Falkenstein 12
Izmir 12
Manchester 12
Poplar 12
Shenyang 12
Vienna 12
Kingston 11
Mexico City 11
Newark 11
Woodbridge 11
Augusta 10
Bogotá 10
Curitiba 10
Elk Grove Village 10
Leawood 10
Mumbai 10
Totale 5.834
Salva come PNG Salva come JPEG
Nome #
Novel Insights into the Pathogenesis of Inflammatory Bowel Diseases 312
Paradoxical psoriasis in a large cohort of patients with inflammatory bowel disease receiving treatment with anti-TNF alpha: 5-year follow-up study 242
FOXP3⁺ T regulatory cell modifications in inflammatory bowel disease patients treated with anti-TNFα agents 224
Infliximab in Steroid-dependent Ulcerative Colitis: Effectiveness and Predictors of Clinical and Endoscopic Remission. 221
Comparison of Quantiferon-TB Gold versus tuberculin skin test for tuberculosis screening in inflammatory bowel disease patients. 208
Prevention of postoperative recurrence with azathioprine or infliximab in patients with Crohn's disease: an open-label pilot study 205
Immune response to influenza A/H1N1 vaccine in inflammatory bowel disease patients treated with anti TNF-α agents: Effects of combined therapy with immunosuppressants. 204
Achievement of sustained deep remission with adalimumab in a patient with both refractory ulcerative colitis and seronegative erosive rheumatoid arthritis 193
Ileal Crohn's disease: CEUS determination of activity 190
Prevalence and natural history of hepatitis B and C infections in a large population of IBD patients treated with anti-tumor necrosis factor-α agents 189
Comparison of performances of infliximab biosimilars CT-P13 versus SB2 in the treatment of inflammatory bowel diseases: a real-life multicenter, observational study in Italy 185
Challenges in crohn’s disease management after gastrointestinal cancer diagnosis 184
Magnesium Absorption in Intestinal Cells: Evidence of Cross-Talk between EGF and TRPM6 and Novel Implications for Cetuximab Therapy 181
Transition from intravenous to subcutaneous biological therapies in inflammatory bowel disease: An online survey of patients 170
Anti-TNF alpha in the treatment of ulcerative colitis: a valid approach for organ-sparing or an expensive option to delay surgery? 166
Early vedolizumab trough levels predict treatment persistence over the first year in inflammatory bowel disease 166
Switching from VEDOlizumab intravenous to subcutaneous formulation in ulcerative colitis patients in clinical remission: The SVEDO Study, an IG-IBD study 158
Therapeutic drug monitoring of anti-TNF-α agents in inflammatory bowel diseases 157
Combination therapy in inflammatory bowel disease – from traditional immunosuppressors towards the new paradigm of dual targeted therapy 157
A 1-year follow-up study on checkpoint inhibitor-induced colitis: results from a European consortium 154
Clinical management of rheumatologic conditions co-occurring with inflammatory bowel diseases 148
Drug-Related Pneumonitis in Patients Receiving Vedolizumab Therapy for Inflammatory Bowel Disease 148
Benefit–risk assessment of golimumab in the treatment of refractory ulcerative colitis 146
Transition of inflammatory bowel disease patients from pediatric to adult care: an observational study on a joint-visits approach 144
Management of perianal fistulas in Crohn's disease: an up-to-date review 143
Impact of COVID-19 pandemic on the daily management of biotechnological therapy in inflammatory bowel disease patients: Reorganisational response in a high-volume Italian inflammatory bowel disease centre 143
Serial Fecal Microbiota Infusions via Colonoscopy for Active Ulcerative Colitis: A Feasibility, Safety, and Translational Monocentric Italian Study 141
Switching from IFX originator to biosimilar CT-P13 does not impact effectiveness,safety and immunogenicity in a large cohort of IBD patients 139
Predictors of Efficacy of Janus Kinase Inhibitors in Patients Affected by Ulcerative Colitis 136
What is the best way to manage screening for infections and vaccination of inflammatory bowel disease patients? 136
Impact of SARS-CoV-2 Infection on the Course of Inflammatory Bowel Disease in Patients Treated with Biological Therapeutic Agents: A Case-Control Study. 135
Crohn's Disease: Radiological Answers to Clinical Questions and Review of the Literature 134
Real-life effectiveness of ustekinumab in inflammatory bowel disease patients with concomitant psoriasis or psoriatic arthritis: An IG-IBD study 134
Challenges in Crohn's Disease Management after Gastrointestinal Cancer Diagnosis 131
Comment on: Emergence of severe spondyloarthropathy-related entheseal pathology following successful vedolizumab therapy for inflammatory bowel disease 131
Cellular and Molecular Determinants of Biologic Drugs Resistance and Therapeutic Failure in Inflammatory Bowel Disease 130
Comparison of Performances of Adalimumab Biosimilars SB5, ABP501, GP2017, and MSB11022 in Treating Patients with Inflammatory Bowel Diseases: A Real-Life, Multicenter, Observational Study 127
Real-world efficacy and safety of vedolizumab in managing ulcerative colitis versus Crohn's disease: results from an Italian multicenter study 125
Therapeutic drug monitoring is more cost-effective than a clinically-based approach in the management of loss of response to infliximab in inflammatory bowel disease: an observational multi-centre study. 125
Changes in admissions, and hospitalization outcomes of IBD patients in an Italian tertiary referral center over a 13-year period 125
Predictors and early markers of response to biological therapies in inflammatory bowel diseases 124
Histologic Disease Persists beyond Mucosal Healing and Could Predict Reactivation in Ulcerative Colitis 124
Dual Targeted Therapy: a possible option for the management of refractory Inflammatory Bowel Disease 120
Radiomics could predict surgery at 10 years in Crohn's disease 119
Rates of Adverse Events in Patients With Ulcerative Colitis Undergoing Colectomy During Treatment With Tofacitinib vs Biologics: A Multicenter Observational Study 119
Anti TNF-α therapy for ulcerative colitis: current status and prospects for the future 117
Effectiveness and safety of vedolizumab in a matched cohort of elderly and nonelderly patients with inflammatory bowel disease: the IG‐IBD LIVE study 115
Early vedolizumab trough levels predict treatment persistence over the first year in inflammatory bowel disease 115
TRPM7 Is Overexpressed in Human IBD-Related and Sporadic Colorectal Cancer and Correlates with Tumor Grade 114
Therapies for inflammatory bowel disease do not pose additional risks for adverse outcomes of SARS-CoV-2 infection: an IG-IBD study 114
Combination therapy in inflammatory bowel disease – from traditional immunosuppressors towards the new paradigm of dual targeted therapy 113
PragmaticTrial Design to Compare Real-world Effectiveness of DifferentTreatments for Inflammatory Bowel Diseases:The PRACTICE-IBD European Consensus 112
Ustekinumab safety and effectiveness in patients with ulcerative colitis: results from a large real-life study 112
Frontiers in drug research and development for inflammatory bowel disease 112
Severe eosinophilic asthma and aspirin-exacerbated respiratory disease associated to eosinophilic gastroenteritis treated with mepolizumab: A case report 110
Clinical, Radiological, and Surgical Risk Factors for Endoscopic Anastomotic Recurrence Following Surgery in Crohn's Disease 109
Novel trends with biologics in inflammatory bowel disease: sequential and combined approaches 108
Challenges in Crohn's Disease Management after Gastrointestinal Cancer Diagnosis 106
SARS-CoV-2 infection in patients with inflammatory bowel disease: comparison between the first and second pandemic waves 106
Novel trends with biologics in inflammatory bowel disease: sequential and combined approaches 103
Switching from IFX originator to biosimilar CT-P13 does not impact effectiveness,safety and immunogenicity in a large cohort of IBD patients 103
Replacement of Adalimumab Originator to Adalimumab Biosimilar for a Non-Medical Reason in Patients with Inflammatory Bowel Disease: A Real-life Comparison of Adalimumab Biosimilars Currently Available in Italy 102
Nonmedical switch of anti-TNF-α biosimilars has no major clinical, pharmacokinetic and psychological impact on patients with IBD - the SAFER Study 101
Use of tofacitinib as first or second-line therapy is associated with better outcomes in patients with ulcerative colitis: data from a real-world study 101
Adalimumab in active ulcerative colitis: a "real-life" observational study 101
Long-term safety of in utero exposure to anti-TNFα drugs for the treatment of inflammatory bowel disease: Results from the multicenter European TEDDY study 101
Orphan patients with inflammatory bowel disease - when we treat beyond evidence 101
An Objective Comparison of Vedolizumab and Ustekinumab Effectiveness in Crohn's Disease Patients' Failure to TNF-Alpha Inhibitors 100
Effectiveness of autologous emulsified stromal vascular fraction tissue injection for the treatment of complex perianal fistulas in inflammatory bowel diseases patients: a pilot study 100
Endoscopic Postoperative Recurrence in Crohn's Disease After Curative Ileocecal Resection with Early Prophylaxis by Anti-TNF, Vedolizumab or Ustekinumab: A Real-World Multicentre European Study 100
Long-Term Effectiveness and Safety of Ustekinumab in Crohn's Disease: Results from a Large Real-Life Cohort Study 99
The PROSit cohort of infliximab biosimilar in IBD: A prolonged follow-up on the effectiveness and safety across Italy 99
Targeting IL12/23 in ulcerative colitis: update on the role of ustekinumab 97
Management of difficult-to-treat patients with ulcerative colitis: focus on adalimumab 97
Therapeutic drug monitoring with vedolizumab in inflammatory bowel disease 97
Letter: SARS-CoV-2 infection in two IBD patients treated with dual targeted therapy 95
Sustained clinical efficacy and mucosal healing of thiopurine maintenance treatment in ulcerative colitis: A real-life study 90
Adaptation of the European Crohn's Colitis Organisation quality of care standards to Italy: The Italian Group for the study of inflammatory bowel disease consensus 88
The thrilling journey of sars-cov-2 into the intestine: From pathogenesis to future clinical implications 86
Diet and nutrients in gastrointestinal chronic diseases 86
The educational role of IBD nurses in Italy in vaccinations: do not miss the moment for COVID-19 83
Effectiveness and Safety of Switching from Intravenous to Subcutaneous Vedolizumab Formulation in Inflammatory Bowel Disease Patients in Clinical Remission 81
The inflammatory bowel disease care manager: Italian state of the art 80
Patient-Reported Outcomes for the Assessment of Sexual Health Among Patients Affected by Inflammatory Bowel Disease 80
Guidance for Fecal Microbiota Transplantation Trials in Ulcerative Colitis: The Second ROME Consensus Conference 76
Morbidly Obese Patient With Ulcerative Colitis Treated With Endoscopic Gastroplasty: A Case Report 76
Reply to managing patients with ulcerative colitis with infliximab in primary and referral gastroenterology centers 73
Autoimmune Pancreatitis in Patients with Inflammatory Bowel Disease: A Real-World Multicentre Collaborative ECCO CONFER Study 47
Innovation and sustainability in immune-mediated diseases: An Italian multidisciplinary consensus across gastroenterology, dermatology, and rheumatology 43
Timing of biologic prophylaxis and postoperative recurrence in Crohn's disease: A real-life cohort study using propensity score weighting 34
Multicenter Real-World Outcomes of Risankizumab in Crohn's Disease: The RESOLVE IG-IBD Study 32
Impact of Psychopathology and Gut Microbiota on Disease Progression in Ulcerative Colitis: A Five-Year Follow-Up Study 31
Clinical Predictive Factors for the Development of Short Bowel Syndrome in a Cohort of Patients with Crohn's Disease: A Prospective Study 28
Effectiveness and safety of mirikizumab in ulcerative colitis: real-world data from the Latium Net 27
Vedolizumab for the prevention and treatment of postoperative recurrence in Crohn's disease: A real- world latium net study 24
Thromboembolic and cardiovascular risk profiles in patients with ulcerative colitis initiating advanced therapies 24
Totale 11.642
Salva come PNG Salva come JPEG
Categoria #
all - tutte 47.255
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 47.255
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022394 0 0 0 70 8 10 10 65 9 25 90 107
2022/20231.127 148 147 78 182 71 130 54 103 143 15 36 20
2023/2024767 18 161 30 72 23 126 45 48 41 39 72 92
2024/20251.734 20 43 137 30 129 65 133 84 207 217 365 304
2025/20264.627 687 236 331 631 752 208 670 202 269 294 195 152
2026/20271.701 170 459 371 701 0 0 0 0 0 0 0 0
Totale 11.642